You Position: Home > Paper
Efficacy of celecoxib in the treatment of hilar cholangiocarcinoma: an analysis of 24 cases
( views:309, downloads:1 )
- Author:
- No author available
- Journal Title:
- WORLD CHINESE JOURNAL OF DIGESTOLOGY
- Issue:
- 34
- DOI:
- 10.3969/j.issn.1009-3079.2009.34.018
- Key Word:
- 塞来西布;肝门部胆管癌;生存率
Abstract： 目的:探讨环氧化酶-2(COX-2)特异性抑制剂塞来昔布(celecoxib) 治疗肝门部胆管癌的临床疗效. 方法:对24例不可切除的肝门部胆管癌患者,采用塞来昔布治疗,并与同期随机的17例患者(对照组)进行前瞻性比较,分析2组生存期、塞来昔布治疗的安全性及其镇痛效果. 结果:塞来西布组的生存期高于未服用组,2 组生存时间有显著性差异(11.5 mo vs 9.6 mo,P<0.05);塞来西布组患者未发生明显的不良反应,他对疼痛缓解的总有效率为83.3%. 结论:塞来昔布可能是治疗肝门部胆管癌安全、有效的新方法.
- [1]Gao-song Wu,Sheng-Quan Zou,Zheng-Ren Liu,etc.Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines[J].2003,(6).
- [2]徐刚,吴恺,王兴鹏,等.塞来昔布与吉西他滨合用对胰腺癌的抑制作用及其机制[J].2005,(14).
- [3]吴高松,武小勇,邹声泉,等.环氧合酶-2反义核酸对人胆管癌细胞增生的影响[J].2003,(6).
- [4]Gao-song Wu,Sheng-Quan Zou,Zheng-Ren Liu,etc.Bile from a patient with anomalous pancreaticobiliary ductal union promotes the proliferation of human cholangiocarcinoma cells via COX-2 pathway[J].2003,(5).
- [5]吴高松,邹声泉.Celecoxib通过环氧合酶-2和前列腺素E2途径抑制胰腺癌JF-305细胞增殖[J].2003,(6).
- [6]康华峰,王西京,刘小旭,等.塞来昔布预防大鼠乳腺癌发生及其机制[J].2006,(11).
- [7]孙学军,石景森,何平.影响胆管癌切除术后的预后因素分析[J].2006,(1).
- [8]Gao-song Wu,Sheng-Quan Zou,Xiao-yong Wu,etc.Effects of Cyclooxygenase-2 Antisense Vector on Proliferation of Human Cholangiocarcinoma Cells[J].2004,(2).
- [9]刘利珍,简捷,吴建兵,等.Nimesulide联合奥沙利铂对人肝癌细胞增殖与凋亡的影响[J].2008,(36).
- [10]刘小旭,康华峰,王西京,等.环氧化酶-2抑制剂预防大鼠化学性乳腺癌[J].2007,(1).
- [11]黄志强.肝门部胆管癌外科治疗观念能否有所转变[J].2008,(1).
- [12]Pathangey LB,Gendler SJ,Pockaj BA,etc.Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin e(2) secretion in patients with breast cancer.[J].2004,11(3).